Immune responses to an inactive vaccine against American cutaneous leishmaniasis together with granulocyte-macrophage colony-stimulating factor

Vaccine. 2002 Jan 31;20(9-10):1365-8. doi: 10.1016/s0264-410x(01)00469-8.

Abstract

The immunological response in healthy subjects to a crude leishmania antigen vaccine (Leishvacin) plus rhGM-CSF without prior Montenegro (DTH) skin testing was evaluated. Fifty-six healthy volunteers received vaccine plus either placebo or rhGM-CSF at day 0, followed by either a vaccine booster or placebo at day 21. IFN-gamma and IL-5 levels were significantly enhanced by day 21. The adjuvant group had a higher percentage of individuals with a significant response to vaccination than the corresponding placebo group. Eighty-six percent of all volunteers were DTH-positive by day 42. Leishvacin is capable of sensitizing lymphocytes from individuals not previously exposed to leishmania antigen. Use of rhGM-CSF enhanced the immune response, indicating that it may improve immunological response to the vaccine.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adjuvants, Immunologic / pharmacology*
  • Animals
  • Double-Blind Method
  • Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology*
  • Humans
  • Hypersensitivity, Delayed / etiology
  • Interferon-gamma / biosynthesis
  • Interleukin-5 / biosynthesis
  • Leishmania mexicana / immunology*
  • Protozoan Vaccines / immunology*
  • Recombinant Proteins
  • Vaccines, Inactivated / immunology

Substances

  • Adjuvants, Immunologic
  • Interleukin-5
  • Protozoan Vaccines
  • Recombinant Proteins
  • Vaccines, Inactivated
  • Interferon-gamma
  • Granulocyte-Macrophage Colony-Stimulating Factor